Lisata Therapeutics, Inc. develops investigational therapies for advanced solid tumors and other serious diseases. Its principal product candidate, certepetide, is a proprietary iRGD cyclic peptide designed to activate an uptake pathway that can improve tumor targeting and penetration by co-administered or tethered anti-cancer agents.
Recurring Lisata news covers clinical and preclinical data involving certepetide, collaborations and license agreements tied to antibody-drug conjugates and other delivery technologies, development-rights changes for regional markets, financial results, business updates, and corporate matters affecting governance or capital structure.
Lisata Therapeutics (Nasdaq: LSTA) announced that Erkki Ruoslahti, M.D., Ph.D., has received the 2022 Albert Lasker Basic Medical Research Award. Recognized for his discovery of integrins, Ruoslahti's work underpins the CendR Platform™, which enhances drug delivery to solid tumors. The CendR platform is central to Lisata's lead clinical program, LSTA1, targeting advanced solid tumors. Ruoslahti's accolades highlight significant contributions to medical science, including over 150 patents. Lisata focuses on developing therapies for challenging cancers, leveraging Ruoslahti's expertise.